OPINION: Balance of Performance has played a crucial role in the success of sportscar racing over recent years and although ...

908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device ...

Shares of 908 Devices (NASDAQ:MASS) climbed ~71% in the premarket on Tuesday after Repligen (NASDAQ:RGEN) offered $70M in cash to acquire the company’s bioprocessing analytics portfolio.

908 Devices sold its desktop portfolio to Repligen for $70 million, reducing $20 million in annual operating losses. 908 Devices expects 2025 revenue of $53 million-$55 million, with EBITDA ...

908 Devices (MASS) announces that it has received a $1.7M order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the ...

On Tuesday, Repligen Corporation (NASDAQ:RGEN) purchased 908 Devices Inc.’s (NASDAQ:MASS) desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.

Analysts expect 908 Devices to post earnings of ($0.35) per share and revenue of $17.05 million for the quarter. 908 Devices Trading Up 8.2 % MASS stock opened at $2.24 on Monday.

The company said, “908 Devices (MASS) expects full year 2025 revenues from continuing operations of $53 million to $55 million, representing 11% to 15% growth compared to 2024 revenue from ...

BOSTON, March 11, 2025--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order ...